Microbiome Therapeutics

Market overview, New development, Future trends 2017 - 2013, IP landscape

A comprehensive study : full market research AND detailed IP landscape!

 

What makes this report unique?

  •  Microbiome as a drug
  • Gastrointestinal disorders, metabolic disorders, auto-immune diseases, CNS disorders, skin diseases
  • Comprehensive competitive analysis : 55 companies
  • 100+ projects, from discovery to clinical stage
  • Competition from non-microbiome drugs
  • Complete Intellectual Property landscape

Dozens of interviews conducted, amongst other: 

  • Mike Berman, Chairman of the Board, Rebiotix
  • David Berry, Founder, Seres Therapeutics; Founder & Board Member, Evelo Therapeutics; General Partner, Flagship Pioneering
  • Didi Daboush, CEO - Founding Partner, MyBiotics Pharma Ltd.
  • Gregory Lambert, CEO, TargEDys
  • Andrew Ritter, Founder & President, Ritter Pharmaceuticals
  • Noah Voreades, MS, Corporate Development Manager, Ritter Pharmaceuticals
  • Dr. Yasser Heakal, PhD, MBA, Assistant Professor of Pharmacology, D'Youville School of Pharmacy, Buffalo, New York, USA
  • Dr. Christian Jobin, Gatorade Trust Professor of Medicine, Program leader Cancer Microbiota and Host Response, University of Florida, Florida, USA
  • Dr. Paul Wischmeyer, Professor of Anesthesiology and Surgery, Director of Perioperative Research, Duke Clinical Research Institute, North Carolina, USA

Date of publication: mid March.

Microbiome Therapeutics

March 2017

4.500,00 €



Why?

To understand

  • The market dynamics including, market drivers, challenges and trends
  • The key evolving market trends
  • The comprehensive market landscape including key players, technologies, products
  • The patent Landscape

To whom?

  • C level
  • Marketing managers
  • Innovation managers  
  • IP managers
  •          BU Managers
  • Investors

 As a very dynamic and promising area, the microbiome is considered as a fantastic opportunity not only to cure but to diagnose. A fast-growing ecosystem is emerging: biopharmaceutical companies, diagnostic companies, service providers…

Considering this trend and the increasing number of companies, we think that a global market research is not a good approach anymore to have a real understanding of the microbiome business. Conversely, industrial property is very important to considere. That's why  Intellisness have decided to produce a series of market research focused on the different segment and integrating not only market data but patent landscape.

The first report is on the Microbiome Therapeutics market. The objective is to understand the microbiome therapeutics market space and answer the following key questions:

· What are the market dynamics including, market drivers, challenges, regulatory issues, business trends, etc.?

· What is the competitive landscape, including key players, technologies, products and non microbiome competitor?

· What is the intellectual property landscape, what are the most innovative companies? Are they the most active on the market?


Contents

1. Objective

2. Scope and methodology

3. Summary

4. Market Dynamics

    4.1 PEST Analysis

   4.2 Evolution

   4.3 Growth Drivers

      4.3.1 Advanced research and associated projects

      4.3.2 Growing industry interest

      4.3.3 Venture capital investment

      4.3.4 Big Pharma and nutraceuticals

      4.3.3 Unmet need

      4.3.4 Physician and patient awareness

   4.4 Barriers and challenges

      4.4.1 Challenging regulatory pathways

      4.4.2 Lack of clinical trial success

      4.4.3 Emerging competition from non-microbiome products

      4.4.4 Perceived overlap between probiotics and microbiome therapies

      4.4.5 Large-scale manufacturing challenges

5. Future Trends

   5.1. 100+ projects in the pipe: race for next generation

   5.2. Market Potential 2017 – 2023

   5.3 Market potential by therapeutic areas

      5.3.1 CDI

      5.3.2 Irritable Bowel Syndrome

      5.3.3 Oral Mucositis

      5.3.4 Skin diseases

      5.3.5 Lactose Intolerance

      5.3.6 Central Nervous System

   5.4 Market potential by geographic area

      5.4.1 US

      5.4.2 Europe

      5.4.3 Japan

6. Competitive Overview

   6.1 Company Profile: Rebiotix

      6.1.1 Overview

      6.1.2 Pipeline

      6.1.3 Technology

      6.1.4 Partnerships

      6.1.5 RBX2660 Phase II trial results – details

      6.1.6 Relevant IP

   6.2 Company Profile: Seres Therapeutics

      6.2.1 Overview

      6.2.2 Pipeline

      6.2.3 Technology

      6.2.4 Partnerships

      6.2.5 SER-109 Phase II trial results – details

      6.2.6 Relevant IP

   6.3 Company Profile: Synthetic Biologics

      6.3.1 Overview

      6.3.2 Pipeline

      6.3.3 Technology

      6.3.4 Partnerships

      6.3.5 Phase II trial results – Details

      6.3.6 Relevant IP

   6.4 Company Profile: Ritter Pharmaceuticals

      6.4.1 Overview

      6.4.2 Pipeline

      6.4.3 Technology

      6.4.4 Partnerships

      6.4.5 Relevant IP

   6.5 Company Profile: AOBiome

      6.5.1 Overview

      6.5.2 Pipeline

      6.5.3 Technology

      6.5.4 Partnerships

      6.5.5 Relevant IP

   6.6 Company Profile: Oragenics

      6.6.1 Overview

      6.6.2 Pipeline

      6.6.3 Technology

      6.6.4 Partnerships

      6.6.5 Relevant IP

   6.7 Company Profile: 4D Pharma

      6.7.1 Overview

      6.7.2 Pipeline

      6.7.3 Technology

      6.7.4 Partnerships

      6.7.5 Relevant IP

   6.8 Company Profile: Second Genome

      6.8.1 Overview

      6.8.2 Pipeline

      6.8.3 Technology

      6.8.4 Partnerships

      6.8.5 Relevant IP

   6.9 Company Profile: Microbiome Therapeutics

      6.9.1 Overview

      6.9.2 Pipeline

      6.9.3 Technology

      6.9.4 Partnerships

      6.9.5 Relevant IP

   6.10 Company Profile: Enterome

      6.10.1 Overview

      6.10.2 Pipeline

      6.10.3 Technology

      6.10.4 Partnerships

      6.10.5 Relevant IP

  7. Other players

       7.1 Players by therapeutic areas

      7.2 Players by stage, from discovery to clinical stage

 8. IP Landscape

    8. 1. Project Overview

      8.1.1 Objective

      8.1.2 Focus Therapeutic Areas

   8.2. Methodology

   8.3. Overall trends and patent family analysis

      8.3.1 Patent Activity

      8.3.2 Global Research Activity (Offices of first filing except EP & PCT)

      8.3.3 Research Activity Trend in key countries

      8.3.4 Patent Filing Strategy by Country

      8.3.5 Patent Filing Strategy – Family Distribution

      8.3.6 Percentage of patent families focusing on various disorders

      8.3.7 Geographical Distribution per therapeutic areas

      8.3.8 Filing Trend per therapeutic area

      8.3.9 Distribution per organization profile

      8.3.10 Distribution per country and organization profile

      8.3.11 Top 20 Applicants

      8.3.12 Top Applicants per region

      8.3.13 Key Assignees per therapeutic area

      8.3.14 Key Academic Institutes

      8.3.15 Key Inventors

      8.3.16 Top Cited Patent Families

      8.3.17 Collaboration Map

 

APPENDIX

Crohn’s Disease – Ongoing Clinical Trials - Details

Clostridium Difficile – Ongoing clinical trials - Details

IBS - Ongoing clinical trial - Details

Oral Mucositis – Ongoing clinical trials - Details

Others – Ongoing clinical trials - Details

Overview of the 48 other players

Therapeutic area categorization

Search Strategy

Relevance Criteria for patent analysis

Patent Data Sanitization

Data and assumption for market sizing

 


Tel +33(0)9 72 57 61 44

Le  Concorde,

24 rue Lamartine

38320 Eybens